Altimmune Q2 net loss $22.8M; initiates Phase 3 MASH trial, positive AUD data

Altimmune, Inc.

Net loss $22.8M ($0.12/share) vs $22.1M ($0.27/share) in Q2 2025; R&D $18.7M, G&A $7.6M.
Cash and investments $519M as of June 30, 2026; gross proceeds $225M from April 2026 offering.
Initiated global PERFORMA Phase 3 MASH trial; 52-week data expected 2029; pemvidutide granted FDA Breakthrough Therapy.
Positive topline RECLAIM Phase 2 AUD: significant reduction in heavy drinking days; Fast Track designation.
Completed enrollment in RESTORE Phase 2 ALD trial; topline data expected H2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.